about
DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriersGenome-wide association studies identify four ER negative-specific breast cancer risk lociGenome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer riskAssociation between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.The importance of a family history of breast cancer in predicting the presence of a BRCA mutationPALB2, CHEK2 and ATM rare variants and cancer risk: data from COGSLarge-scale genotyping identifies 41 new loci associated with breast cancer risk.Genetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study.Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.A focus group study on breast cancer risk presentation: one format does not fit allMale breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2.Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC)TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancerEvaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation CarriersCommon genetic variants and modification of penetrance of BRCA2-associated breast cancer2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy.Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions.Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancerBeliefs about optimal age and screening frequency predict breast screening adherence in a prospective study of female relatives from the Ontario site of the Breast Cancer Family RegistryCommon non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association ConsortiumCommon breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction.Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study.Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors.Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1.Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.Influence of perceived breast cancer risk on screening behaviors of female relatives from the Ontario site of the Breast Cancer Family RegistryGenetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers.Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies.Does perceived risk predict breast cancer screening use? Findings from a prospective cohort study of female relatives from the Ontario site of the breast cancer family registryEvidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation.A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general populationIdentification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer riskInherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer.Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancerGenetic predisposition to in situ and invasive lobular carcinoma of the breast.Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia.Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study.Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapyAdherence to breast and ovarian cancer screening recommendations for female relatives from the Ontario site of the Breast Cancer Family Registry
P50
Q21144874-7BCC1A22-6A45-4B55-B147-0D92C93D2913Q24622610-1B740CD5-E4D6-4A20-8FD5-25599EF11AF1Q27008356-B8912523-A86D-4823-AA62-9609F485E2A2Q27851709-78808B61-6282-4B5B-84E7-D6C89246B4A8Q28386650-DF164E07-5559-4EB3-86D6-843B4033925FQ28584533-7C35D33E-3F2C-48C4-A9C4-C37998DE8E74Q29416989-C15BF5D5-FF7A-4764-A561-CB437486869EQ29417068-71C51758-3890-4667-97EF-B08BC401142AQ30252854-BE657B73-DB66-4BD4-8B64-B7614362AD50Q30374367-365901DE-C2D8-48D6-9FDB-BE7BB46B081FQ30541811-9799A5BE-D6F6-41B0-A36E-6BE7805444E6Q31043651-9CC867E1-BB46-4C8F-8C29-E82CEDCA11FBQ31082788-6FEB7ED4-7716-4599-92D3-C448BDC7110CQ33566957-78B60D3D-A7B1-43AD-8A0F-921EFE27F1D5Q33614244-104EB0E6-954C-42EA-9420-E67AD91DC597Q33742096-33E4F270-6668-4A46-B776-E5D8EA4A7D22Q33848895-EEF83B68-E33F-4E59-830C-8CEF89D3CBADQ34038964-EF6275D1-9334-4AA0-BF44-D18628FBE764Q34181322-06932D77-5CD0-4146-9EB6-460F26E5A0FAQ34334167-CF8F2837-AEF7-4360-B0E9-9B74EDD4EAD3Q34379032-F2A24E69-D6D2-4D62-9785-031D7BF02FCAQ34394665-AEFEC302-19F7-492D-8857-837D7CF4460DQ34613673-ED0DD23E-FE9F-4E81-877A-4592A4A3F057Q34898735-EEA9D04A-2F4D-4AB9-A1F2-2EFE21CAE3DCQ34903062-9EFFFFB9-6A46-4C65-A856-26BAA3BE264EQ34963894-439F31E4-1D61-49FC-BB01-400E40763587Q35013740-2E229443-D791-437A-A30B-0B65EC97E293Q35022825-84B437BA-361A-4495-A6B1-2C124DC4536DQ35022847-874943EC-91C4-437E-ABE2-55944DE8CBF9Q35049656-A4471526-20A5-4276-A2E6-2998872EEF2EQ35064451-3316BA6E-8AFA-44E5-84DD-BC9E199198FBQ35089479-51E734E5-F0C6-4A74-B1E2-0E9DD43F1324Q35102646-35C04924-A008-41A1-B105-831AF767F600Q35104068-9198D085-16ED-4DD6-9D1D-76DF925E35C5Q35114576-E951E475-2A7E-4EF5-82BE-FFDD7100D97CQ35151684-6105ECE4-11D2-4EC2-B577-0AEFD3E1A1F5Q35155449-0D685E18-B185-4658-A407-EAB209F1D1FBQ35179897-ABC4FBAD-E206-4A54-A05D-24190591F7CAQ35218520-074767E0-4667-4D2F-99A9-408D32F0C441Q35231571-155B5A82-787C-4614-A235-A7FAEA55CB70
P50
description
Canadees onderzoeker
@nl
Canadian researcher
@en
canadisk forsker
@nb
name
Gord Glendon
@da
Gord Glendon
@de
Gord Glendon
@en
Gord Glendon
@es
Gord Glendon
@fr
Gord Glendon
@nb
Gord Glendon
@nl
Gord Glendon
@nn
Gord Glendon
@sl
Gord Glendon
@sv
type
label
Gord Glendon
@da
Gord Glendon
@de
Gord Glendon
@en
Gord Glendon
@es
Gord Glendon
@fr
Gord Glendon
@nb
Gord Glendon
@nl
Gord Glendon
@nn
Gord Glendon
@sl
Gord Glendon
@sv
prefLabel
Gord Glendon
@da
Gord Glendon
@de
Gord Glendon
@en
Gord Glendon
@es
Gord Glendon
@fr
Gord Glendon
@nb
Gord Glendon
@nl
Gord Glendon
@nn
Gord Glendon
@sl
Gord Glendon
@sv
P106
P2038
Gord_Glendon
P21
P27
P31
P496
0000-0001-8630-6673